Herein, a multifunctional traceable and ultrasound-responsive drug targeted delivery system based on indocyanine green (ICG) and folic acid (FA) covalently conjugated lipid microbubbles (ILMBs-FA) is proposed. After encapsulation of the anticancer drug resveratrol (RV), the composite (RILMBs-FA) with fluorescence and ultrasound imaging capacity was studied for highly sensitive dual-imaging guided tumor targeted therapy. The resulting RILMBs-FA with an average particle size of 1.32 AE 0.14 mm exhibited good stability and biocompatibility characteristics. The RILMBs-FA featured a high RV loading ratio and the encapsulated RV has been demonstrated to be released from the microbubbles triggered by ultrasound (US) waves. In addition, it was found that the linked FA could facilitate a high cellular uptake of RILMBs-FA via the FA receptor-mediated endocytosis pathway. Compared to free RV and RILMBs, RILMBs-FA with US irradiation demonstrated a more significant tumor cell-killing efficacy mediated by apoptosis in vitro. Eight hours post intravenous injection of RILMBs-FA, the composites showed maximum accumulation in tumorous tissues according to in vivo fluorescence and US images. This ultimately led to the best tumor inhibition effect among all tested drugs under US irradiation. In vivo biosafety evaluations showed that RILMBs-FA featured high biocompatibility characteristics and no significant systemic toxicity over the course of one month. Taken in concert, these results demonstrate the versatility of this drug delivery system with dual-imaging and ultrasound-triggered drug release characteristics for potential future applications in cancer theranostics.
Introduction
In recent decades, cancer has become one of the most serious global health threats to humans.
1 Thus, the development of cancer theranostics with high efficacy has become one of the crucial goals in medicine. 2 Traditional treatment regimens for cancer include surgical excision, radiotherapy and chemotherapy. 3 However, frequent and serious side effects with poor survival rates are oen observed. 4 These drawbacks include the systemic radiotoxicity and toxicity of chemotherapeutic drugs that are oen non-specic to different tumors. 5 In recent years, one study has focused on simultaneous and precise noninvasive imaging diagnosis and targeted chemotherapy, generally regarded as a novel and an ideal strategy in the treatment of cancer. 6 Because of advantages such as real-time data acquisition, low cost operation, high safety and portability, ultrasound (US) imaging has become one of the most commonly used clinical tumor diagnostic tools. [7] [8] [9] Combined with tumortargeted ultrasound contrast agents, e.g. tumor targeted microbubbles or nanobubbles, US imaging can help observe the distribution of contrast agents and tumor structures with both high resolution and sensitivity. 10, 11 Moreover, US irradiation with focus and non-invasive deep penetration capacity in so tissue has been demonstrated to enhance the intercellular uptake of drugs and trigger the release of drugs from the bubbles. [12] [13] [14] [15] For example, Yan et al. have developed various functionalized bubbles as US imaging contrast agents and UStriggered therapeutic drug delivery carriers for the development of tumor theranostics.
15
Dual-modality imaging with only one contrast agent has been regarded to be a more precise diagnostic tool for tumors. 16, 17 Among various clinical tumor imaging modalities, near-infrared (NIR) uorescence imaging has been extensively applied in clinical applications, e.g. guided tumor resection procedures, due to its high sensitivity and imaging speed. [18] [19] [20] Recently, some researchers have reported uorescent bubbles that integrated US imaging and uorescence imaging as dualimaging contrast agents for the diagnosis of tumors.
16,21-23 For instance, Mai et al. have developed a cyanine 5.5 conjugated nanobubble as a tumor-selective contrast agent for tumor ultrasound/uorescence dual-imaging. 16 However, most of the used uorescence molecules have not been approved by the Food and Drug Administration (FDA) which limits their future clinical translation. In addition, the used dyes were mostly encapsulated in the bubbles, which would lead leak of the small molecule dye that affect the imaging capacity. Indocyanine green (ICG) represents an FDA-approved uorescent molecule. 20, 24 Because of its low toxicity and high uorescence yield, ICG has been widely used for disease diagnosis in clinical applications. 25 However, ICG features some drawbacks such as poor colloid-and photo-stability, low specicity, and short halflife in the bloodstream, which limit further and more extensive applications. 26 To solve these issues, free ICG is typically conjugated with a vehicle, e.g. a polymer, liposomes, lipid, transition metal dichalcogenides, etc. to form a composite. 24, [27] [28] [29] [30] In this study, a biocompatible lipid-PEG microbubble has been developed as a multifunctional platform for the use as a tumor theranostic (Scheme 1). Free ICG and the tumortargeted molecule folic acid (FA) were covalently conjugated to microbubbles (ILMBs-FA). This tumor-targeted uorescence bubble integrated US and uorescence dual-imaging capacities. In order to equip the material with tumor therapeutic features, the known anticancer drug resveratrol (RV) was encapsualated into the ILMBs-FA to form the theranostic agent RILMBs-FA. [31] [32] [33] The obtained RILMBs-FA with uniform morphology and great biocompatibility not only improved the stability of RV with ICG further enhancing the half-life, but also functioned as an US-triggered RV-targeted delivery carrier. As a US and uores-cent dual-imaging probe, the uorescence imaging ability was used to detect the cellular target uptake, in vivo biodistribution, and tumor accumulation of the theranostic agent. The US imaging capacity was further used to conrm the tumor accumulation of RILMBs-FA. Guided by the dual-imaging results, the targeted anticancer efficacy of RILMBs-FA with or without US irradiation was demonstrated both in vitro and in vivo.
Experimental section

Materials
Resveratrol (purity $ 99%) and peruoropropane (C 3 F 8 ) was purchased from Sigma (St. Louis, MO, USA). Disaturated RILMBs-FA without RV (ILMBs-FA) were also prepared as the contrast. In addition, the RILMBs-FA without FA (RILMBs) was prepared according to the similar preparation method of RILMBs-FA when the DSPE-PEG-FA was replaced by DSPE-PEG. The bright and uorescence images of the particles and cells were observed by confocal laser scanning microscopy (FV1200, OLYMPUS, Japan). The size and zeta of the particles were detected using a Zetasizer Nano ZS system (Malvern Instruments, Malvern, UK). UV-Vis spectrophotometer (Shimadzu/ Model UV-1601PC, Kyoto, Japan) and spectrouorometer (F900, Edinburgh Instruments Ltd, UK) were respectively used to detect the absorption and uorescence spectra of the particles.
RV encapsulation efficiency and US-triggered release
As mentioned in Section 2.3, the obtained MBs were rstly dialyzed in deionized water for 12 h. To determine the free RV concentration, the optical absorbance of the dialysate was measured with a UV-Vis spectrometer at 304 nm and compared against a calibration curve to calculate the amount of unencapsulated RV. The encapsulated RV in MBs was determined as unencapsulated RV subtracted from the total RV used. The encapsulation efficiency (EE) of RV was calculated according to the eqn (1) as below:
In addition, the RV release ratio triggered by US irradiation was evaluated. In detail, RILMBs-FA (1 mL) was added into the Eppendorf tube, which was sealed by paralm. The US transducer was lled with ultrasonic coupling agent and the tube was placed onto the surface of transducer. Aer 60 s US irradiation (1 MHz transducer, 1 MPa US intensity), these tubes were centrifuged for 25 min at 13 000g. The supernatant was collected and extracted by CHCl 3 . The cumulative release efficiency (CRE) was detected every 10 s during 60 s US irradiation. The CRE was calculated according to the following eqn (2):
Cellular uptake
HepG2 cells were seeded in 20 mm Petri dishes. Aer cultured for 24 h, free ICG, RILMBs, RILMBs-FA + FA and RILMBs-FA (with same ICG concentration) were incubated with cells for 5 h. Aerwards, the treated cells were washed by PBS thrice, xed by 4% paraformaldehyde for 10 min, and stained by 0.2 mg mL
Shanghai, China) for 10 min. The uorescence images of the cells were captured by confocal laser scanning microscopy and the uorescence intensity of the cells was detected using ow cytometer (Beckman Coulter, Miami, FL) according to the protocol.
In vitro hemolysis test
For hemolysis test of RILMBs-FA, 1 mL whole blood was collected from health mouse. Through centrifugation, the red blood cells (RBCs) were separated. Various concentration of RILMBs-FA in PBS was incubated with RBCs. Aer 1 h incubation at 37 C, the treated RBCs were centrifuged with10 000 rpm for 1 min. The absorbance of the supernatants was detected by UV-Vis spectrophotometer at 541 nm. The hemolytic percent (HP) was calculated according to the following eqn (3):
where A t , A pc , and A nc are the absorbance value of the supernatant of the test sample, water treated sample (positive control) and PBS treated sample (negative control), respectively.
In vitro anticancer efficacy and apoptosis staining
A standard CCK-8 assay (7Sea PharmTech, Shanghai, China) was utilized to evaluate the cytotoxicity of the in vitro anticancer efficacy. Firstly, ILMBs-FA at predetermined concentrations (10, 50, 150, 300, 600 mg mL À1 ) were cultured with adherent cells.
Aer 24 h incubation, DMEM media containing 10% CCK-8 were added into each well and the cells were cultured for further 30 min at 37 C. A Multimode Plate Reader (EnVision;
PerkinElmer) was used to detect the absorbance value of the treated cells at 450 nm wavelength to characterize the cell viability. Moreover, RV, RILMBs and RILMBs-FA (at the same concentration of RV) and LMBs with or without US irradiation were treated with HepG2 cells for 3 h. Aerwards, the cells were irradiated by US for 60 s and then were incubated for 24 h. The viability of the treated cells was also detected by CCK-8 assay. In addition, these treated cells were stained by Hoechst 33258 dye and the uorescence images of the cells were captured by confocal laser scanning microscopy.
In vivo uorescence imaging and biodistribution study
The uorescence signal of the tumor bearing mice were detected pre-injected and 0.1, 2, 8 and 12 h post-injected with ICG, RILMBs and RILMBs-FA by a commercial Maestro in vivo imaging system (CRi Inc., Woburn, USA) at 735 nm excitation wavelength. In addition, the uorescence signal of excised heart, liver, spleen, lungs, kidneys and tumor at 8 h postinjection of ICG, RILMBs and RILMBs-FA was also detected. The content of ICG, RILMBs and RILMBs-FA in these samples was determined by ICG uorescence.
In vitro and in vivo US imaging
In vitro US imaging was obtained by a Doppler ultrasonic diagnostic apparatus (Esaote Healthy Co., Ltd., Italy) with 12 MHz linear transducer. The ICG, RILMBs and RILMBs-FA (with same concentration of bubbles) were dispersed in PBS and mixed with agarose gel to form a pie shape phantom. The US imaging was taken from the horizontal section of the phantom. In vivo US imaging were conducted on tumor-bearing mice at pre-injection (0 h) and 8 h post-injection of RILMBs-FA intravenously.
In vivo anticancer efficacy and toxicity study
HepG2 tumor bearing mice were randomly divided into ve groups (n ¼ 5) and then were treated by intravenously injection of saline (control), free RV, RILMBs + US and RILMBs-FA and RILMBs-FA + US, respectively. During the treatment, the tumor volume and body weight of the mice were monitored every three days. The tumor volume (TV) was calculated as the eqn (4):
The tumor growth change was showed by relative tumor volumes (RTV) which were calculated as the follow eqn (5):
where V 0 represents the initial tumor volume. In addition, healthy mice (n ¼ 5) were intravenously injected with 150 mL RILMBs-FA at a dose of 15 mg kg collected for complete blood counts evaluations at the First People's Hospital of Shangqiu, Henan province. Furthermore, the heart, liver, spleen, lung and kidney of the treated mice at 14 days post-injection of RILMBs-FA were collected, xed by 4% paraformaldehyde overnight and dehydrated in 25% sucrose for hematoxylin and eosin (H&E, Sigma) staining. The HE staining images were observed using an inverted microscope.
Results and discussion
Preparation and characterization of RILMBs-FA
RILMBs-FA was synthesized as shown in Scheme 1. DSPE-PEG 2000 -FA and DSPE-PEG 2000 -ICG were around the bubbles to form a hydrophilic monolayer and stabilize the entire bubble structure. Fig. 1a and b show high magnication optical microscopy images and green uorescence images using uo-rescent microscope and indicate that RILMBs-FA exhibited a uniform spherical shape. The average diameter and zeta potentials of RILMBs-FA were determined to be 1.29 AE 0.03 mm and À31.1 AE 0.69 mV, respectively ( Fig. 1c and d ). Fig. 2a shows that the UV-Vis spectra of RILMBs-FA, which simultaneously exhibited the absorbance peaks of ICG and RV at wavelengths of 780 nm and 304 nm, respectively, demonstrating the existence of both ICG and RV in RILMBs-FA. As shown in the uorescence spectra results shown in Fig. 2b and c, RILMBs-FA exhibited both ICG and RV uorescence emission signals at 800 nm and 400 nm, respectively. These results demonstrate that RILMBs-FA features optical properties of both ICG and RV. In addition, we evaluated the inuence of scatting on the absorbance and uorescence spectra. The results were shown in Fig. S1 , † the feature peak absorbance and uores-cence intensity of the RILMBs-FA increased linearly with enhancement of their concentration (0.5, 0.25, 0.125, 0.0625, 0.03125 mg mL À1 ), which indicated the scatting didn't affect the absorbance and uorescence of the RILMBs-FA at the concentration of 0.5, 0.25, 0.125, 0.0625, 0.03125 mg mL À1 . Fig. 3a shows the uorescence stability of ICG and RILMBs-FA in aqueous solution. Aer 36 h of storage at 37 C, the ICG uo-rescence intensity of RILMBs-FA remained constant and no signicant change compared to its initial intensities could be observed. However, the uorescence intensity of free ICG decreased rapidly compared to its initial intensity. It was reported that free ICG could aggregate that induced uorescence signal quenching and decrease. 24, 30 The average size of RILMBs-FA in water and PBS slightly increased over the course of 36 h (Fig. 3b and S2 †) . In addition, RV leakage could be detected aer 36 h (Fig. 3c) . These results indicate that RILMBs-FA featured a good stability, likely due to the PEG surrounding RILMBs-FA.
Aer calculation according to the eqn (1), the maximum RV and ICG encapsulation efficiency of RILMBs-FA were 99.1 AE 1.3% and 23.6 AE 2.1%, respectively. The US-triggered RV release ratio of RILMBs-FA was detected upon exposure to US irradiation for 60 s. The drug release prole of RILMBs-FA was recorded as functions of the cumulative RV release ration and the US treatment time. As shown in Fig. 3d , upon US irradiation with 1 MPa ultrasound pressure and 1 MHz frequency for 60 s, the drug release ratio was found to increase with increasing irradiation time. The highest RV release rate was 89.7 AE 3.1% aer US irradiation for 60 s. These results showed that RILMBs-FA exhibited a suitable US-triggered drug release capability, likely due to the destruction of microbubbles leading to drug release. [34] [35] [36] [37] 3.2 In vitro cellular uptake and biocompatibility Fig. 4a shows that intense ICG red uorescence could be observed in the perinuclear region in RILMBs-FA treated cells compared to that of free ICG and RILMBs treated cells. This latter nding indicated that a sufficient amount of RILMBs-FA could enter the cells. However, aer pre-treatment with free FA, HepG2 incubated with RILMBs-FA showed very little ICG red uorescence, likely due to free FA blocking the FA receptor on the HepG2 surface. In addition, a similar cellular uptake behavior of RILMBs-FA was observed by FCM and determined to be 48.9 AE 4.2%, much higher than that of free ICG, RILMBs, RILMBs-FA + FA and RILMBs-FA. This series of results demonstrates that RILMBs-FA may enter cells via the FA receptor mediated endocytosis pathway.
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As shown in Fig. 4c , RILMBs-FA at a concentration range of 10 to 600 mg mL À1 induced a low hemolysis ratio that was similar to the negative control. This nding indicated that RILMBs-FA featured appropriate hemocompatibility characteristics. Moreover, the negligible cytotoxicity of the carrier ILMBs-FA without RV suggested that the prepared bubbles exhibited excellent in vitro biocompatibility properties (Fig. 4d) . 
In vitro anticancer efficacy and apoptosis detection
As shown in Fig. 5a , free RV, RILMBs and RILMBs-FA with the same RV concentration ranging between 0 and 40 mg mL
À1
demonstrated an enhanced cell-killing ability in a dosedependent manner. Under US irradiation for 60 s, RILMBs-FA exhibited the highest cell death rate. As a control, cells treated by lipid-bubbles (LMBs) with US irradiation for 60 s showed no signicant viability decrease, indicating that no cytotoxicity of LMBs plus US irradiation could be observed. The enhanced in vitro anticancer efficacy of RILMBs-FA could likely be attributed to the efficient FA mediated active targeting effect and the enhanced RV release rate triggered by US irradiation. Moreover, the cell nuclei of cells treated with free RV, RILMBs and RILMBs-FA plus US irradiation were stained by Hoechst 33258 to evaluate the cell death type. As shown in Fig. 5c , cells treated by RILMBs and RILMBs-FA with US irradiation showed nuclear condensation, similar to that of RV with US irradiation. In contrast, the control cells showed a uniform nucleoplasm.
Nuclear condensation has been reported to be a unique characteristic of apoptotic cells. Therefore, the results obtained throughout this study indicated the cell death mediated by apoptosis was induced by the release of RV, triggered by US irradiation.
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In vivo uorescence imaging and biodistribution
As shown in Fig. 6a, 6 min post injection, strong uorescence signals could be obtained throughout the entire mouse body, likely from the presence of free ICG, RILMBs and RILMBs-FA in the bloodstream. Upon increasing the time, increased uores-cence signals were observed in the tumor regions, especially in the RILMBs-FA group compared to that in ICG and RILMBs groups. 8 h post injection, the tumor uorescence intensity of RILMBs-FA treated mice reached a peak value, which was further conrmed by the uorescence images of the corresponding excised tumor (Fig. 6a) . Fig. 6b shows the uorescence signal change in the tumor region 12 h post injection of free ICG, RILMBs and RILMBs-FA, respectively. This nding showed that the tumor uorescence signal in RILMBs-FA group was signicantly higher than that of the free ICG and RILMBs groups at all studied time points. In addition, Fig. 6c shows ex vivo uorescence quantitative results of harvested tumors and hearts, livers, spleens, lungs and kidneys from euthanized mice 12 h post injection. The liver and kidney tissue in the groups of free ICG, RILMBs and RILMBs-FA showed strong uorescence signals, indicating that the particles were mainly metabolized via the hepatic and renal pathway. 41 Remarkably, because of the enhanced permeability and retention (EPR) effect and the FA mediated tumor targeted effect, [42] [43] [44] [45] the tumor uorescence signal in the RILMBs-FA group proved to be stronger than that in the free ICG and RILMBs group.
In vitro and in vivo US imaging
The microbubbles in RILMBs-FA resulted in a well enhanced US imaging capacity. As shown in Fig. 7a and b , the RILMBs-FA as well as RILMBs with equal number of bubbles featured the same contrast-enhancing image intensity, higher than that of PBS and ICG. Pre injection of RILMBs-FA, the inner tumor tissues exhibited less US signal. However, the tumor accumulation of RILMBs-FA aer systemic injection of RILMBs-FA was clearly manifested by enhanced echogenicity of tumor ultrasound images (Fig. 7c) . The quantitative results showed that the US signal intensity in the tumors of mice 8 h post injection of RILMBs-FA was about 9.3 folds compared with that pre injection (Fig. 7d) . This result implied that the RILMBs-FA may potentially be useful as highly sensitive US imaging probes in enhanced US imaging. 
In vivo anticancer efficacy and toxicity evaluation
Guided by in vivo uorescence and US dual-imaging, 8 h post injection of RILMBs-FA, US irradiation was applied to the tumors for 1 min. Among the treated groups including control, RV, RILMBs + US, RILMBs-FA, and RILMBs-FA + US groups, the RILMBs-FA + US group exhibited the most remarkable tumor growth suppression and no tumor relapse aer about one month of treatment (Fig. 8a) . During the treatment period for one month, the body weight of mice in all groups did not decrease (Fig. 8b) , and there were no obvious histological lesions of mice in RILMBs-FA + US group according to HE staining images (Fig. 9a) .
Furthermore, the parameters of blood in RILMBs-FA injected mice 0, 7 and 14 days post-injection, including aspartate aminotransferase (AST), alanine aminotransferase (ALT), white blood cell count (WBC), red blood cell count (RBC), hemoglobin (HGB), mean platelet volume (MPV), hematocrit (HCT), mean corpuscular hemoglobin concentration (MCHC) and mean corpuscular volume (MCV) were demonstrated to be normal compared to those values of the control mice (Fig. 9b-d) . These results demonstrated that RILMBs-FA exhibiting suitable in vivo biocompatibility characteristics may represent a promising material for future clinical applications in tumor therapy.
Conclusions
In summary, we have prepared an integrated theranostic agent, RILMBs-FA, that was demonstrated to covalently conjugate ICG and FA, and encapsulate RV to lipid-PEG microbubbles for uo-rescence and US imaging-guided tumor target therapy in vitro and in vivo. Due to the coating with PEG and lipid, the obtained RILMBs-FA exhibited excellent stability and biocompatibility characteristics. US irradiation could efficiently trigger RV release from RILMBs-FA, likely due to the destruction of the microbubbles. The modied FA facilitated a highly efficient cellular uptake of RILMBs-FA via FA receptor-mediated endocytosis pathway. The conjugated ICG and microbubbles resulted in uo-rescence and US imaging capabilities of RILMBs-FA that was demonstrated both in vitro and in vivo. The obtained imaging results showed that RILMBs-FA could actively target tumor tissues and reach a peak accumulation 8 h post injection. Guided by the imaging diagnostic results, in vitro and in vivo experiments indicated that compared with free RV, RILMBs-FA plus US irradiation featured an excellent anticancer efficacy induced by apoptosis, without signicant systemic toxicity. Taken in concert, the results indicate that RILMBs-FA may be a promising tumor-integrated theranostic agent for the use in future nanomedicine applications.
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